Orexigen Therapeutics, Inc. 's shares gained 3.8% on Mar 27, 2017, after the company announced that it has entered into a commercialization and distributorship agreement with Italian pharmaceutical company, Bruno Farmaceutici, for its obesity drug, Contrave (EU trade name: Mysimba). Notably, this is the company's fourth partnership in Europe. Under the terms of the deal, Bruno Farmaceutici will be responsible for gaining regulatory approval in Canada and for all commercialization activities and expenses. On the other hand, Orexigen would supply Contrave tablets for an agreed transfer price, based on certain regulatory and sales milestone payments. Orexigen's shares gained 137.4% so far this year, significantly outperforming an increase of 5.7% by the Zacks classified Medical-Biomed/Genetics industry.